Prognostic significance of early tumor shrinkage in metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based combination therapy - PubMed
an hour ago
- #prognostic biomarker
- #immune checkpoint inhibitors
- #metastatic renal cell carcinoma
- Early tumor shrinkage at first imaging assessment is an independent prognostic indicator for overall survival in metastatic renal cell carcinoma patients treated with first-line immune checkpoint inhibitor-based combination therapies.
- Patients were stratified into four shrinkage categories, with median overall survival being not reached for those with 50-100% and 30-<50% shrinkage, 34.7 months for 0-<30% shrinkage, and 30.8 months for progression, highlighting a correlation between greater early shrinkage and improved survival outcomes.
- In multivariate analysis, along with early tumor shrinkage, prior nephrectomy, presence of bone or liver metastasis, and histological subtype remained significant independent predictors of overall survival.